IDEXX Laboratories, Inc. vs Vanguard Real Estate Index Fund ETF — how do they compare? IDEXX Laboratories, Inc. trades at $557.02 (market cap $44.48B), while Vanguard Real Estate Index Fund ETF trades at $99.46. The key difference: Vanguard Real Estate Index Fund ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | VNQ | |
|---|---|---|
Market Cap | $44.48B | — |
Sector | Health | — |
52-Week High | $766.68 | $100.07 |
52-Week Low | $520.87 | $87.00 |
Enterprise Value | $45.38B | — |
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
VNQ trades at $99.5, down 0.52% on the day, with a bullish technical signal driven by strong moving average alignment. The ETF's expense ratio of 0.13% remains a competitive advantage, and recent news highlights its 12% year-to-date total return through mid-July 2026. Dividend payments are scheduled, with the next payout of $0.86 set for June 26, 2026.
Outlook is cautiously optimistic, supported by technical strength and cost efficiency, but risks include sensitivity to interest rates and potential overbought conditions. The ETF's domestic focus offers stability, yet investors should weigh the impact of Treasury yield fluctuations on real estate valuations.
Trailing returns across standard periods
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →